Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.50 |
| ▸ | IGF1R | P08069 | 9/20 | 0.49 |
| ▸ | INSR | P06213 | 7/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756701 | 0.90 | INSR (0.47) | EGFRERBB2IGF1RINSR | |
| SCHEMBL3764610 | 0.85 | CDK19 (0.48) | EGFRERBB2IGF1RINSR | |
| SCHEMBL3719751 | 0.85 | IGF1R (0.46) | EGFRERBB2IGF1RINSRMAPK14 | |
| SCHEMBL3767817 | 0.85 | IGF1R (0.56) | EGFRERBB2IGF1RINSRMAPK14 | |
| SCHEMBL3767735 | 0.84 | CDK19 (0.47) | EGFRERBB2IGF1RINSR | |
| SCHEMBL3761771 | 0.84 | INSR (0.54) | EGFRERBB2IGF1RINSR | |
| SCHEMBL3772445 | 0.82 | IGF1R (0.59) | EGFRERBB2IGF1RINSRMAPK14 | |
| SCHEMBL3767709 | 0.82 | EGFR (0.57) | EGFRERBB2IGF1RINSRMAPK14 | |
| SCHEMBL3767706 | 0.82 | EGFR (0.57) | EGFRERBB2IGF1RINSRMAPK14 | |
| SCHEMBL3725890 | 0.82 | CDK19 (0.64) | EGFRERBB2IGF1RINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | claimed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | EGFR 328/4885ERBB2 58/4885IGF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.